Physician profile
Joyce Wall
NPI 1457949000
$4,924.18
in general payments reported to CMS, 2019-2025
21 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.75 · 2023: $1,026 · 2024: $1,399 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,320.27 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $683.15 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $616.37 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $550.32 | 2023-2025 | |
| Novo Nordisk INC | $365.30 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $219.02 | 2023-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $184.25 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $180.38 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $172.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $122.85 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $95.72 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Lundbeck LLC | $90.42 | 2025 | Rexulti |
| Janssen Biotech, INC. | $73.03 | 2022-2023 | Symtuza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.16 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $52.36 | 2023-2025 | Vpriv, Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $28.90 | 2023 | Symtuza |
| Xeris Pharmaceuticals, INC. | $22.30 | 2025 | Gvoke Hypopen |
| Baxter Healthcare | $20.93 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.90 | 2024 | Caplyta |
| Philips North America LLC | $20.20 | 2023 | |
| Pfizer INC. | $19.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.